{"analyses":[{"ciLowerLimit":"0.849","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.152","estimateComment":"Cabazitaxel 25 mg/m\\^2 vs Docetaxel 75 mg/m\\^2","groupDescription":"Hazard ratio was estimated using a Cox Proportional Hazards regression model. The Cox proportional hazard model was adjusted by ECOG PS score at baseline, measurable disease at baseline, and region with commercial availability of cabazitaxel at the time of randomization.","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Hazard Ratio (HR)","paramValue":"0.989"},{"ciLowerLimit":"0.913","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.236","estimateComment":"Cabazitaxel 20 mg/m\\^2 vs Docetaxel 75 mg/m\\^2","groupDescription":"Hazard ratio was estimated using a Cox Proportional Hazards regression model. The Cox proportional hazard model was adjusted by ECOG PS score at baseline, measurable disease at baseline, and region with commercial availability of cabazitaxel at the time of randomization.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Hazard Ratio (HR)","paramValue":"1.063"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.86","upperLimit":"5.78","value":"5.3"},{"groupId":"OG001","lowerLimit":"3.91","upperLimit":"5.09","value":"4.4"},{"groupId":"OG002","lowerLimit":"4.60","upperLimit":"5.72","value":"5.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"391"},{"groupId":"OG001","value":"389"},{"groupId":"OG002","value":"388"}],"units":"Participants"}],"description":"PFS: time interval between date of randomization to date of first occurrence of any of following events: tumor progression according to Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1; Prostate Specific Antigen (PSA) progression; pain progression or death due to any cause. Analysis was performed by Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Docetaxel (TXT) 75 mg/m\\^2 IV infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant's refusal.","id":"OG000","title":"Docetaxel 75 mg/m^2"},{"description":"Cabazitaxel 20 mg/m\\^2 IV infusion on Day 1 of each 21 -day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant's refusal.","id":"OG001","title":"Cabazitaxel 20 mg/m^2"},{"description":"Cabazitaxel 25 mg/m\\^2 IV infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant's refusal.","id":"OG002","title":"Cabazitaxel 25 mg/m^2"}],"paramType":"MEDIAN","populationDescription":"ITT population included all randomized participants.","reportingStatus":"POSTED","timeFrame":"Baseline up to tumor progression, PSA progression, pain progression or death (maximum duration: 51 months)","title":"Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}